Stocks and InvestingStocks and Investing
Thu, February 3, 2022
Wed, February 2, 2022
Tue, February 1, 2022
Mon, January 31, 2022
Sun, January 30, 2022

Brian Skorney Maintained (VRTX) at Buy and Held Target at $240 on, Jan 30th, 2022


Published on 2024-10-27 19:29:25 - WOPRAI, Brian Skorney
  Print publication without navigation


Brian Skorney of Baird, Maintained "Vertex Pharmaceuticals Incorporated" (VRTX) at Buy and Held Target at $240 on, Jan 30th, 2022.

Brian has made no other calls on VRTX in the last 4 months.



There are 9 other peers that have a rating on VRTX. Out of the 9 peers that are also analyzing VRTX, 2 agree with Brian's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Paul Matteis of "Stifel" Maintained at Hold with Increased Target to $222 on, Thursday, January 27th, 2022
  • Do Kim of "Piper Sandler" Downgraded from Buy to Hold and Decreased Target to $218 on, Friday, November 19th, 2021


These are the ratings of the 7 analyists that currently disagree with Brian


  • Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy and Held Target at $275 on, Thursday, January 27th, 2022
  • Evan Seigerman of "BMO Capital" Upgraded from Hold to Buy and Increased Target to $274 on, Thursday, January 20th, 2022
  • Liisa Bayko of "Evercore ISI Group" Maintained at Buy and Held Target at $265 on, Wednesday, December 22nd, 2021
  • Mohit Bansal of "Wells Fargo" Initiated at Buy and Held Target at $270 on, Thursday, December 9th, 2021
  • Brian Abrahams of "RBC Capital" Maintained at Buy with Increased Target to $265 on, Thursday, December 2nd, 2021
  • Debjit Chattopadhyay of "Guggenheim" Maintained at Strong Buy with Increased Target to $286 on, Wednesday, December 1st, 2021
  • Robyn Karnauskas of "Truist Securities" Maintained at Strong Buy with Increased Target to $341 on, Wednesday, December 1st, 2021